Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Gils

Showing results (11-20 of 162) with videos related to

Pageof 17
Sort By:
Seminars in Thrombosis and Hemostasis|March 19, 2013
Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpinPaul J Declerck, Ann Gils
Journal of Clinical Pharmacology|February 25, 2015
Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practiceNiels Vande Casteele, Ann Gils
Digestive Diseases and Sciences|April 29, 2015
Preemptive Dose Optimization Using Therapeutic Drug Monitoring for Biologic Therapy of Crohn's Disease: Avoiding Failure While Lowering Costs?Niels Vande Casteele, Ann Gils
Thrombosis and Haemostasis|February 26, 2004
The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitorsAnn Gils, Paul J Declerck
Current Drug Targets|March 9, 2016
Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized TreatmentErwin Dreesen, Ann Gils, Severine Vermeire
JAAD Case Reports|November 6, 2019
Eczematous eruption after guselkumab treatment for psoriasisBirgit Reyn, Tom Hillary, Ann Gils
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 25, 2015
Reply: To PMID 24486408Filip Baert, Séverine Vermeire, Ann Gils
The AAPS Journal|November 23, 2016
Validation of a Drug-Resistant Anti-Adalimumab Antibody Assay to Monitor Immunogenicity in the Presence of High Concentrations of AdalimumabSumin Bian, Marc Ferrante, Ann Gils
Seminars in Thrombosis and Hemostasis|March 5, 2013
Thrombin activatable fibrinolysis inhibitor: a putative target to enhance fibrinolysisEllen Vercauteren, Ann Gils, Paul J Declerck
Clinical Pharmacology and Therapeutics|August 18, 2019
Achieving Mucosal Healing in Inflammatory Bowel Diseases: Which Drug Concentrations Need to Be Targeted?Nathalie Van den Berghe, Ann Gils, Debby Thomas
Pageof 17

Showing results (11-20 of 162) with videos related to

Sort By:
Pageof 17
Seminars in Thrombosis and Hemostasis|March 19, 2013
Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpinPaul J Declerck, Ann Gils
Journal of Clinical Pharmacology|February 25, 2015
Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practiceNiels Vande Casteele, Ann Gils
Digestive Diseases and Sciences|April 29, 2015
Preemptive Dose Optimization Using Therapeutic Drug Monitoring for Biologic Therapy of Crohn's Disease: Avoiding Failure While Lowering Costs?Niels Vande Casteele, Ann Gils
Thrombosis and Haemostasis|February 26, 2004
The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitorsAnn Gils, Paul J Declerck
Current Drug Targets|March 9, 2016
Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized TreatmentErwin Dreesen, Ann Gils, Severine Vermeire
JAAD Case Reports|November 6, 2019
Eczematous eruption after guselkumab treatment for psoriasisBirgit Reyn, Tom Hillary, Ann Gils
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 25, 2015
Reply: To PMID 24486408Filip Baert, Séverine Vermeire, Ann Gils
The AAPS Journal|November 23, 2016
Validation of a Drug-Resistant Anti-Adalimumab Antibody Assay to Monitor Immunogenicity in the Presence of High Concentrations of AdalimumabSumin Bian, Marc Ferrante, Ann Gils
Seminars in Thrombosis and Hemostasis|March 5, 2013
Thrombin activatable fibrinolysis inhibitor: a putative target to enhance fibrinolysisEllen Vercauteren, Ann Gils, Paul J Declerck
Clinical Pharmacology and Therapeutics|August 18, 2019
Achieving Mucosal Healing in Inflammatory Bowel Diseases: Which Drug Concentrations Need to Be Targeted?Nathalie Van den Berghe, Ann Gils, Debby Thomas
Pageof 17